Study patient demographics and disease characteristics
| Patient . | Age (y) . | Primary diagnosis . | Transplant type . | Transplant regimen . | Day+ TMA diagnosed . | TMA complications . | Day+ TPE started . | Day+ rituximab started . | TMA outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | neuroblastoma | autologous | CEM (MA) | +23 | HTN, PRES, seizures, polyserositis, cardiac tamponade, acute dialysis | +82 69 sessions | +40 10 doses | ESRD, HTN |
| 2 | 2 | neuroblastoma | autologous | CEM (MA) | +9 | HTN, AKI | +36 23 sessions | +22 4 doses | resolved |
| 3 | 6.5 | neuroblastoma | autologous | CEM (MA) | +111 | HTN, AKI | none | +113 4 doses | resolved |
| 4 | 17 | X-linked lymphoproliferative disorder | allogeneic | C-FM (RIC) | +47 | HTN, PRES, seizures, acute dialysis | +64 38 sessions | +50 4 doses | ESRD, HTN |
| 5 | 3 | acute lymphoblastic leukemia | allogeneic | TBI/CY (MA) | +30 | HTN, AKI | none | +31 2 doses | resolved |
| 6 | 2.5 | acute lymphoblastic leukemia | allogeneic | TBI/CY (MA) | +35 | HTN, PRES, seizures, multiorgan failure, acute dialysis | +40 25 sessions | +37 4 doses | resolved |
| Patient . | Age (y) . | Primary diagnosis . | Transplant type . | Transplant regimen . | Day+ TMA diagnosed . | TMA complications . | Day+ TPE started . | Day+ rituximab started . | TMA outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | neuroblastoma | autologous | CEM (MA) | +23 | HTN, PRES, seizures, polyserositis, cardiac tamponade, acute dialysis | +82 69 sessions | +40 10 doses | ESRD, HTN |
| 2 | 2 | neuroblastoma | autologous | CEM (MA) | +9 | HTN, AKI | +36 23 sessions | +22 4 doses | resolved |
| 3 | 6.5 | neuroblastoma | autologous | CEM (MA) | +111 | HTN, AKI | none | +113 4 doses | resolved |
| 4 | 17 | X-linked lymphoproliferative disorder | allogeneic | C-FM (RIC) | +47 | HTN, PRES, seizures, acute dialysis | +64 38 sessions | +50 4 doses | ESRD, HTN |
| 5 | 3 | acute lymphoblastic leukemia | allogeneic | TBI/CY (MA) | +30 | HTN, AKI | none | +31 2 doses | resolved |
| 6 | 2.5 | acute lymphoblastic leukemia | allogeneic | TBI/CY (MA) | +35 | HTN, PRES, seizures, multiorgan failure, acute dialysis | +40 25 sessions | +37 4 doses | resolved |
CEM, carboplatin-etoposide-melphalan; C-FM, Alemtuzumab(Campath)-Fludarabine-melphalan; Day+, day after stem cell transplantation; ESRD, end-stage renal disease; HTN, hypertension; MA, myeloablative; PRES, posterior reversible encephalopathy syndrome; RIC, reduced intensity conditioning; TBI/CY, total body irradiation-cyclophosphamide; TMA, stem cell transplant-associated; TPE, therapeutic plasma exchange.